Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration
The incidence and mortality of pancreatic adenocarcinoma (PC) are expected to increase in the coming years, with survival rates remaining poor due to limited treatment options. KRAS mutations, present in over 70% of PC cases, drive aggressive tumor behavior through metabolic reprogramming and immune...
Saved in:
| Main Authors: | Giuseppe Defazio, Federico Scolari, Sara Fancelli, Simone Polvani, Daniele Lavacchi, Lucia Picariello, Alessandro Tubita, Michaela Luconi, Lorenzo Antonuzzo, Andrea Galli, Serena Pillozzi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1613773/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elevated KRAS protein level is associated with better survival in pancreatic cancer
by: S. M. Stålberg, et al.
Published: (2025-07-01) -
KRAS4B is required for placental development
by: Marie-Albane Minati, et al.
Published: (2025-08-01) -
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
by: Mahmoud Yousef, et al.
Published: (2025-04-01) -
Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01) -
Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-07-01)